Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
ELOX was delisted on the 13th of October, 2023.
35 hedge funds and large institutions have $7.33M invested in Eloxx Pharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 14 reducing their positions, and 6 closing their positions.
8% less funds holding
Funds holding: 38 → 35 (-3)
37% less capital invested
Capital invested by funds: $11.7M → $7.33M (-$4.34M)
43% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 14
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
50% less call options, than puts
Call options by funds: $1K | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$20.1K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$16.8K |
| 3 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
+$14K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$10.7K |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$10.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$391K |
| 2 |
Two Sigma Advisers
New York
|
-$115K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$106K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$59K |
| 5 |
VF
Virtu Financial
New York
|
-$54K |
ELOX Hedge Fund Activity: Q1 2022 in Review
35 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) for Q1 2022, worth a combined $7.33M — down 37% from $11.7M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ELOX and 3 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 8 added.
The largest buyer was Bank of America, adding an estimated $20.1K. The largest seller was Anson Funds Management, exiting entirely with an estimated $391K sold.
- 35 institutional investors held Eloxx Pharmaceuticals, Inc. Common Stock (ELOX) as of Q1 2022, down from 38 in Q4 2021.
- Funds reported $7.33M of Eloxx Pharmaceuticals, Inc. Common Stock stock for Q1 2022, down 37% quarter-over-quarter.
- 3 funds opened new Eloxx Pharmaceuticals, Inc. Common Stock positions in Q1 2022 and 6 closed out, a net change of -3 holders.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock buyer in Q1 2022 was Bank of America, an estimated $20.1K added.
- The largest Eloxx Pharmaceuticals, Inc. Common Stock seller in Q1 2022 was Anson Funds Management, an estimated $391K sold.
Based on aggregated 13F filings for Q1 2022.